Care for children with atopic dermatitis in the Netherlands during the COVID‐19 pandemic: Lessons from the first wave and implications for the future von Ragamin, Aviël, Wijs, Linde E. M., Hijnen, Dirk‐Jan, Arends, Nicolette J. T., Schuttelaar, Marie L. A., Pasmans, Suzanne G. M. A., Bronner, Madelon B.

Volltext

Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study von de Wijs, Linde E. M., van Egmond, Sven, Devillers, Arjan C. A., Nijsten, Tamar, Hijnen, DirkJan, Lugtenberg, Marjolein

Volltext

Effects of dupilumab treatment on patch test reactions: A retrospective evaluation von de Wijs, Linde E. M., van der Waa, José D., Nijsten, Tamar, Silverberg, Jonathan I., Kunkeler, Amalia C. M., Hijnen, Dirk J.

Volltext

Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences von Olydam, Jill I., Wijs, Linde E. M., Nijsten, Tamar E. C., Rosmalen, Joost, Hijnen, Dirk Jan

Volltext

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry von Bosma, Angela L., de Wijs, Linde E.M., Hof, Michel H., van Nieuwenhuizen, Beau R., Gerbens, Louise A.A., Middelkamp-Hup, Maritza A., Hijnen, DirkJan, Spuls, Phyllis I.

Volltext

EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab von Olydam, Jill I., de Wijs, Linde E.M., Dik, Willem A., Røpke, Mads A., Da Rosa, Joel Correa, Hijnen, Dirk Jan

Volltext

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, th... von Bosma, Angela L., de Wijs, Linde E.M., Hof, Michel H., van Nieuwenhuizen, Beau R., Gerbens, Louise A.A., Middelkamp-Hup, Maritza A., Hijnen, DirkJan, Spuls, Phyllis I.

Volltext